Study of PYX-106 in Solid Tumors
- Conditions
- Solid Tumor
- Interventions
- Drug: PYX-106
- Registration Number
- NCT05718557
- Lead Sponsor
- Pyxis Oncology, Inc
- Brief Summary
The primary objective of this study is to determine the recommended dose(s) of PYX-106 in participants with relapsed/refractory solid tumors.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 60
-
Participants with histologically or cytologically confirmed solid tumors who have relapsed, been non-responsive, or have developed disease progression through standard therapy.
-
Histologically or cytologically confirmed solid tumors (see details below):
For the dose escalation, the following solid tumors are allowed in participants who have relapsed, been non-responsive, or have developed disease progression through standard therapy and in participants for whom standard of care therapy that prolongs survival is unavailable or unsuitable (according to the Investigator and after informing the Medical Monitor): non small cell lung cancer (without driver mutations/translocations), breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.
-
Clinical sites must provide archived tissue or conduct fresh tumor biopsy (formalin-fixed paraffin-embedded [FFPE]; enough to create a minimum of 14 slides). Fresh biopsy pre-treatment is preferred, archival tissue (preferably obtained within 1 year prior to the first infusion of PYX-106) is acceptable if fresh biopsy is not medically feasible, per Investigator, at Screening. Both fresh and archival tissue samples must be collected by core needle biopsy or surgical resection. Fine needle aspirates are not permitted.
-
Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.
-
Participant must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumor (RECIST) Version 1.1 criteria (by local Investigator). Participant must have radiographic evidence of disease progression per Investigator following the most recent line of treatment.
-
Life expectancy of >3 months, in the opinion of the Investigator.
- History of another malignancy except for the following: adequately treated local basal cell or squamous cell carcinoma of the skin; in situ cervical carcinoma, adequately treated; other adequately treated Stage 1 or 2 cancers currently in complete remission; any other cancer that has been in complete remission for >2 years or cancer of low risk of recurrence; or any treated or monitored indolent cancer that is unlikely to cause mortality in 5 years.
- Known symptomatic brain metastases requiring >10 mg/day of prednisolone (or its equivalent) at the time of signing informed consent.
- Continuance of toxicities due to prior anti-cancer agents that do not recover to Grade 1 prior to start of PYX-106 treatment, except for alopecia or endocrine deficiencies treated with stable hormone replacement therapy.
- Presence of Grade ≥2 peripheral neuropathy.
- Major surgery within 4 weeks prior to the start of PYX-106 treatment, as defined by the Investigator.
- Received palliative radiation therapy within 14 days prior to the start of PYX-106 treatment.
- Received a live vaccine within 28 days prior to the first dose of study treatment and while participating in the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description PYX-106 Dose Escalation PYX-106 Participants will receive escalating doses of PYX-106 to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of PYX-106, and to determine the recommended dose(s).
- Primary Outcome Measures
Name Time Method Number of Participants Who Experience an Adverse Event (AE) Day 1 up to approximately 19 months Type, incidence, seriousness and causality of AEs based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0. Any clinically significant changes in clinical laboratory parameters, vital signs, and electrocardiogram (ECG) parameters will be recorded as AEs.
Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) Day 1 to Day 28
- Secondary Outcome Measures
Name Time Method Area Under the Time Concentration Curve from Time 0 to the End of the Dosing Interval (AUCtau) of PYX-106 Day 1 up to approximately 2 years Duration of Response (DOR) Day 1 up to approximately 2 years Progression Free Survival (PFS) Day 1 up to approximately 2 years Disease Control Rate (DCR) Day 1 up to approximately 2 years Area Under the Time Concentration Curve from Time 0 to the Last Quantifiable Concentration (AUC0-t) of PYX-106 Day 1 up to approximately 2 years Time to Response Day 1 up to approximately 2 years Area Under the Time Concentration Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of PYX-106 Day 1 up to approximately 2 years Maximum Concentration (Cmax) of PYX-106 Day 1 up to approximately 2 years Time to Maximum Concentration (Tmax) of PYX-106 Day 1 up to approximately 2 years Half Life (t1/2) of PYX-106 Day 1 up to approximately 2 years Objective Response Rate (ORR) Day 1 up to approximately 2 years Overall Survival (OS) Day 1 up to approximately 2 years
Trial Locations
- Locations (20)
Winship Cancer Institute of Emory University
🇺🇸Atlanta, Georgia, United States
HonorHealth Research Institute
🇺🇸Scottsdale, Arizona, United States
University of California San Diego
🇺🇸La Jolla, California, United States
University of Southern California
🇺🇸Los Angeles, California, United States
SCRI- HealthOne Denver
🇺🇸Denver, Colorado, United States
University of Chicago Medicine
🇺🇸Chicago, Illinois, United States
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Gabrail Cancer and Research Center
🇺🇸Canton, Ohio, United States
Lifespan - Rhode Island Hospital
🇺🇸Providence, Rhode Island, United States
NEXT Oncology
🇺🇸Irving, Texas, United States
NEXT Virginia
🇺🇸Fairfax, Virginia, United States
Universitair Ziekenhuis Leuven - Campus Gasthuisberg
🇧🇪Leuven, Flemish Brabant, Belgium
Grand Hôpital de Charleroi - Notre Dame
🇧🇪Charleroi, Hainaut, Belgium
Universitair Ziekenhuis Gent
🇧🇪Gent, Oost-Vlaanderen, Belgium
Cliniques Universitaires Saint-Luc
🇧🇪Brussels, Belgium
Hospital Universitari Dexeus
🇪🇸Barcelona, Spain
START Madrid - Hospital Universitario Fundación Jiménez Díaz
🇪🇸Madrid, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain
HM Centro Integral Oncológico Clara Campal
🇪🇸Madrid, Spain
Hospital Clínico Universitario de Valencia
🇪🇸Valencia, Spain